Deepinder Goyal's wearable startup Temple launched with novel metrics like BrainFlow, claiming to track blood flow to the brain. Research papers on its website explicitly state it cannot directly measure cerebral blood flow, sparking a heated debate on X. This public spat has exposed a glaring lack of regulatory clarity for health-tracking wearables made in India.
How We Got Here
The recent contentious battle on X over Deepinder Goyal’s Temple brought India’s wearable validation gap into sharp focus. Current regulations allow manufacturers to sell physiological trackers without the clinical trials expected of medical devices.
The Numbers
- Temple claims to track BrainFlow (relative changes in blood flow to the brain) and Entropy (body’s effort to shed heat).
- Its own website research papers explicitly state Temple cannot directly measure cerebral blood flow.
- Temple confirmed Brain Flow Index is a relative optical signal index, correlating with transcranial Doppler ultrasound measurements in the middle cerebral artery.
- The metric currently offers two applications within its fitness app, including cardio intensity comparison.
- A California-based Indian founder highlighted the absence of an established playbook for making wearables in India.
What Happens Next
🇮🇳 Why This Matters for India
For Bangalore and Pune's health tech founders, this regulatory void means navigating product development and marketing claims without a clear blueprint.
The Take
The larger story here is India's gaping regulatory void for health-tracking wearables. Without a clear validation playbook, product managers are flying blind, and the next Temple controversy is inevitable.
Source:
Inc42 ↗